The effect of treating patients with anaemia in diabetic nephropathy to different target haemoglobin levels with epoetin beta

Trial Profile

The effect of treating patients with anaemia in diabetic nephropathy to different target haemoglobin levels with epoetin beta

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2009

At a glance

  • Drugs Epoetin beta (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms ESA-2
  • Most Recent Events

    • 09 Feb 2009 Status is now discontinued, as reported by ISRCTN: Current Controlled Trials.
    • 25 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top